INT1531

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1978
Last Reported 2010
Negated 0
Speculated 3
Reported most in Abstract
Documents 34
Total Number 37
Disease Relevance 15.14
Pain Relevance 3.39

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Mention Frequency
plasma 5
blood 2
tubes 1
excretory 1
vessels 1
[[]] (Canis lupus)
Pain Term Frequency Confidence Heat
bradykinin 58 99.92 Very High Very High Very High
Potency 7 99.62 Very High Very High Very High
ischemia 50 99.60 Very High Very High Very High
anesthesia 21 99.54 Very High Very High Very High
tolerance 58 99.28 Very High Very High Very High
antagonist 62 98.72 Very High Very High Very High
beta blocker 22 98.60 Very High Very High Very High
narcan 3 96.76 Very High Very High Very High
Catecholamine 3 88.88 High High
Pseudotolerance 6 87.40 High High
Disease Term Frequency Confidence Heat
Hypoxia 542 99.96 Very High Very High Very High
Increased Venous Pressure Under Development 103 99.80 Very High Very High Very High
Hypotension 7 99.76 Very High Very High Very High
Diuresis 1 99.68 Very High Very High Very High
Cv Unclassified Under Development 35 99.60 Very High Very High Very High
Renal Disease 3 99.24 Very High Very High Very High
Stress 89 98.72 Very High Very High Very High
Acute Decompensated Heart Failure (ADHF) 8 98.64 Very High Very High Very High
Papillomavirus Infection 392 98.40 Very High Very High Very High
Hypertension 70 98.32 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Pharmacological properties of (2R,4R)-2-(o-hydroxyphenyl)-3-(3-mercaptopropionyl)-4- thiazolidinecarboxylic acid (rentiapril, SA 446), a potent inhibitor of angiotensin converting enzyme, were examined.
Negative_regulation (inhibitor) of angiotensin converting enzyme
1) Confidence 0.57 Published 1987 Journal Arzneimittelforschung Section Abstract Doc Link 3034298 Disease Relevance 0.17 Pain Relevance 0
It is demonstrated from these results that SQ 29 852 has comparable potency with captopril to inhibit angiotensin converting enzyme (ACE) activity and as common a pharmacological profile as ACEI.
Negative_regulation (inhibit) of angiotensin converting enzyme associated with potency
2) Confidence 0.57 Published 1991 Journal J. Pharmacobio-dyn. Section Abstract Doc Link 1812274 Disease Relevance 0.34 Pain Relevance 0.09
It is demonstrated from these results that SQ 29 852 has comparable potency with captopril to inhibit angiotensin converting enzyme (ACE) activity and as common a pharmacological profile as ACEI.
Negative_regulation (inhibit) of ACE associated with potency
3) Confidence 0.57 Published 1991 Journal J. Pharmacobio-dyn. Section Abstract Doc Link 1812274 Disease Relevance 0.34 Pain Relevance 0.09
The mechanism of the hypotensive response produced by inhibition of the angiotensin converting enzyme was studied in pentobarbital anesthetized dogs.
Negative_regulation (inhibition) of angiotensin converting enzyme associated with hypotension
4) Confidence 0.56 Published 1978 Journal Eur. J. Pharmacol. Section Abstract Doc Link 212276 Disease Relevance 0.39 Pain Relevance 0.03
Hypotension induced by inhibition of angiotensin-converting enzyme in pentobarbital-anesthetized dogs.
Negative_regulation (inhibition) of angiotensin-converting enzyme associated with anesthesia
5) Confidence 0.56 Published 1978 Journal Eur. J. Pharmacol. Section Title Doc Link 212276 Disease Relevance 0.44 Pain Relevance 0.13
The effects of Captopril (SQ14,225), an inhibitor of angiotensin-converting enzyme, given intravenously in a dose of 0.3 mg/kg ws studied in intact anaesthetized dogs. 2.
Negative_regulation (inhibitor) of angiotensin-converting enzyme
6) Confidence 0.54 Published 1981 Journal Clin. Exp. Pharmacol. Physiol. Section Abstract Doc Link 7008989 Disease Relevance 0.08 Pain Relevance 0
These data demonstrate that MK-421 and its parent diacid are potent, long-lasting orally active inhibitors of ACE.
Negative_regulation (inhibitors) of ACE
7) Confidence 0.46 Published 1981 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 6259322 Disease Relevance 0 Pain Relevance 0.03
The new ACE inhibitor, spiraprilat, as well as enalaprilat (30 micrograms/kg i.v.) effectively decreased mean aortic pressure (30%), LVEDP (20%), and TPR (30%) and increased stroke volume (SV) CO, and dP/dt/P.
Negative_regulation (inhibitor) of ACE associated with heart rate under development
8) Confidence 0.43 Published 1993 Journal J. Cardiovasc. Pharmacol. Section Abstract Doc Link 7505361 Disease Relevance 0.27 Pain Relevance 0.05
The acute regional hemodynamic effects of spirapril diacid, a novel nonsulfhydryl angiotensin-converting enzyme inhibitor, and enalapril diacid at an equidepressor dose were examined in anesthetized dogs by simultaneously measuring renal, coronary, vertebral arterial and aortic blood flow.
Negative_regulation (inhibitor) of angiotensin-converting enzyme in blood
9) Confidence 0.43 Published 1991 Journal Arch Int Pharmacodyn Ther Section Abstract Doc Link 1888230 Disease Relevance 0.06 Pain Relevance 0
The angiotensin converting enzyme inhibitors (ACEI)-induced decrease in the systolo-diastolic pressor responses to vagal stimulation was reversed by naloxone (0.1 mg/kg iv).
Negative_regulation (decrease) of angiotensin converting enzyme associated with narcan
10) Confidence 0.43 Published 1985 Journal Neuropeptides Section Abstract Doc Link 3001577 Disease Relevance 0 Pain Relevance 0.16
Comparison of acute hemodynamic effects of MC-838, a new angiotensin-converting enzyme inhibitor, with captopril in anesthetized dogs.
Negative_regulation (inhibitor) of angiotensin-converting enzyme associated with anesthesia
11) Confidence 0.40 Published 1986 Journal Jpn. J. Pharmacol. Section Title Doc Link 3012164 Disease Relevance 0.12 Pain Relevance 0.10
Renal effects of perindoprilat, an angiotensin-converting enzyme inhibitor, in the anesthetized dog.
Negative_regulation (inhibitor) of angiotensin-converting enzyme associated with anesthesia
12) Confidence 0.40 Published 1989 Journal J. Cardiovasc. Pharmacol. Section Title Doc Link 2468959 Disease Relevance 0.09 Pain Relevance 0.10
Angiotensin-converting enzyme inhibitors in the therapy of renal diseases.
Negative_regulation (inhibitors) of Angiotensin-converting enzyme associated with renal disease
13) Confidence 0.40 Published 2004 Journal J. Vet. Pharmacol. Ther. Section Title Doc Link 15500563 Disease Relevance 0.65 Pain Relevance 0.05
Cardiovascular effects of the new angiotensin-converting-enzyme inhibitor, cilazapril, in anesthetized and conscious dogs.
Negative_regulation (inhibitor) of angiotensin-converting-enzyme associated with anesthesia
14) Confidence 0.40 Published 1986 Journal J. Cardiovasc. Pharmacol. Section Title Doc Link 2419701 Disease Relevance 0.17 Pain Relevance 0.10
Cilazapril is a new angiotensin-converting-enzyme inhibitor.
Negative_regulation (inhibitor) of angiotensin-converting-enzyme
15) Confidence 0.40 Published 1986 Journal J. Cardiovasc. Pharmacol. Section Abstract Doc Link 2419701 Disease Relevance 0.16 Pain Relevance 0
The parent diacid (N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro of MK-421 inhibited hog plasma angiotensin converting enzyme (ACE) by 50% (I50) at a concentration of 1.2 nM and was 17 times more potent than captopril.
Negative_regulation (inhibited) of ACE in plasma
16) Confidence 0.38 Published 1981 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 6259322 Disease Relevance 0 Pain Relevance 0.04
The parent diacid (N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro of MK-421 inhibited hog plasma angiotensin converting enzyme (ACE) by 50% (I50) at a concentration of 1.2 nM and was 17 times more potent than captopril.
Negative_regulation (inhibited) of angiotensin converting enzyme in plasma
17) Confidence 0.33 Published 1981 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 6259322 Disease Relevance 0 Pain Relevance 0.04
The renal vascular and excretory responses to intrarenal bradykinin were obtained in anesthetized dogs receiving the angiotensin-converting enzyme inhibitor, captopril, and the neutral endopeptidase inhibitor SQ 28,603 (N-[2-(mercaptomethyl)-1-oxo-3-phenylpropyl]-beta-alanine) given individually and together.
Negative_regulation (inhibitor) of angiotensin-converting enzyme in excretory associated with bradykinin
18) Confidence 0.24 Published 1994 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 8169834 Disease Relevance 0 Pain Relevance 0.13
Potentiation of the renal responses to bradykinin by inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in anesthetized dogs.
Negative_regulation (inhibition) of angiotensin-converting enzyme associated with anesthesia and bradykinin
19) Confidence 0.21 Published 1994 Journal J. Pharmacol. Exp. Ther. Section Title Doc Link 8169834 Disease Relevance 0.17 Pain Relevance 0.27
Whether this pulmonary haemodynamic effect could be a consequence of reduced angiotensin II levels is unknown because ACE inhibition increases bradykinin levels [22], which may dilate pulmonary vessels [23].
Negative_regulation (inhibition) of ACE in vessels associated with bradykinin
20) Confidence 0.20 Published 2004 Journal Crit Care Section Body Doc Link PMC522832 Disease Relevance 0.50 Pain Relevance 0.13

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox